|Articles|November 14, 2017
CRF Health’s TrialMax Touch® Selected for Pediatric Rare Disease Phase II Study
Advertisement
CRF Health has been selected by a specialty pharmaceutical company for its latest pediatric rare disease Phase II study. CRF Health's TrialMax Touch® handheld device alone with other solutions will be utilized to collect quality of life readings and alleviate the burden of data entry for caregivers.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Gilead’s Single-Tablet Bictegravi/Lenacapavir Regimen Shows Positive Phase III ARTISTRY-1 Results in Virologically Suppressed Adults with HIV
2
Improving Site Satisfaction Through Better Technology and Collaboration
3
Advarra and IgniteData Partner to Streamline eSource-to-EDC Data Transfer
4
Getting Clinical Outsourcing Right
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
